Please note: The information displayed on this page might be outdated.
Targovax: Oncolytic adenovirus armed w immune stimulating transgene targeting basket of I-O indications. Strong results from Part 1 (ONCOS-102/Keytruda combo) trial in anti-PD1 refractory melanoma: 33% ORR in 9 pts: 1 CR, 2 PRs; immune act. in all 9 pts. Upcoming milestones: randomized data, Ph 1b/2 (mesothelioma, n=31) w/chemo: Jan 2020; Ph 1, Part 2 data (melanoma comb w/Keytruda, n=21): 1H2020; updates from collab partners in peritoneal metastasis & prostate exp 2020
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Clinical Stage
Phase l or ll, Pre-Clinical Stage
Disease Space
Anti-infectives, Antivirals, Immuno-Oncology, Immunotherapy, Oncology
Finance
Pre-earnings
Industry
Biotechnology
Listing
Europe, Public
Market Cap
<100MM
Therapeutic Modalities
Platform Technology, Vaccine
Website:
Profiles:
Address:
Lilleakerveien 2 C
Oslo, NO-0283
Norway

Top 10 Holders of Targovax ASA

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Nordea Investment Management AB (Norway) 7.74 5,023,498 4.58 Funds 7/31/20
Fjärde AP-fonden 4.73 3,000,000 2.74 Funds 6/30/20
KLP Kapitalforvaltning AS 1.36 1,031,244 0.94 Stakes 12/31/19
Storebrand Asset Management AS 0.47 295,000 0.27 Funds 8/31/20
Handelsbanken Fonder AB 0.16 99,669 0.09 Funds 8/31/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.